← Human Trials & Peer-Reviewed Studies
Effect of a leucine-rich supplement in combination with nutrition and physical exercise in advanced cancer patients: A randomized controlled intervention trial.
Plain-language guide to PMID 32340904 (2020): randomized controlled trial of Copper (Supplement) in 12 patients.
Key Facts
- PMID
- 32340904
- Journal
- Clinical nutrition (Edinburgh, Scotland)
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Storck LJ et al. (9 authors)
- DOI
- 10.1016/j.clnu.2020.04.008
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
Branched-chain amino acids and specifically leucine stimulate protein synthesis and may overcome an anabolic resistance in malnourished and cachectic cancer patients.
Who Took Part
The abstract describes 12 patients taking part.
PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.
The intervention group received a leucine-rich supplement in combination with a nutrition and physical exercise program.
Patients in the control group received standard care.
How the Study Was Run
The design is described as randomized.
The patients were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Primary endpoint was physical function measured with the short physical performance battery (SPPB).
Secondary endpoints were further physical performance tests, nutritional status, dietary intake, fatigue, quality of life (QoL) and clinical course.
All parameters were evaluated at baseline, after three and at six months.
What Was Measured
Topics PubMed links to this paper include Cachexia, Combined Modality Therapy, Dietary Supplements, Exercise, Exercise Test, Exercise Therapy and Fatigue.
Author keywords: Cancer, Dietary counselling, Leucine, Physical exercise and Whey protein.
What This Means in Plain Language
The paper is a randomized study of Copper (Supplement) in 12 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2020 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.